Please login to the form below

Not currently logged in
Email:
Password:

Zelboraf

This page shows the latest Zelboraf news and features for those working in and with pharma, biotech and healthcare.

Novartis wins key adjuvant Taf/Mek approval in Europe

Novartis wins key adjuvant Taf/Mek approval in Europe

Taf/Mek competes directly with Roche's Zelboraf (vemurafenib) and Cotellic (cobimetinib) combination in melanoma, but has been outselling its rival, particularly after Roche’s duo failed to hit the mark

Latest news

More from news
Approximately 10 fully matching, plus 39 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    But there are downsides too. It’s worth noting that Roche’s BRAF-targeting drug Zelboraf (vemurafenib) for melanoma has seen mixed results in other tumours, suggesting that ‘histologic context’ – ie

  • Pharma deals during April 2014 Pharma deals during April 2014

    Indeed a whopping $1.5bn payment depends on the results of the on-going combination trial against Roche's Zelboraf.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Chris Bowden joins Agios Chris Bowden joins Agios

    During this time he worked on major cancer medicines, such as melanoma drug Zelboraf (vemurafenib) and Erivedge (vismodegib) for patients with unresectable, locally advanced or metastatic basal cell carcinoma.

  • Kite Pharma appoints Zelboraf scientist as CMO Kite Pharma appoints Zelboraf scientist as CMO

    Keith Nolop joins US cancer biotech from Plexxikon. Dr Keith Nolop, one of the chief scientists behind the development of Roche's personalised skin cancer drug Zelboraf, has been appointed chief ... During this time, he was clinical lead for the

  • AstraZeneca hires Roche’s Pascal Soriot as CEO

    This merger has spawned such drugs as cancer treatments Avastin, Herceptin and Zelboraf, and is deemed to be one of the more successful pharma deals of recent years, while during that

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics